Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in patients ages… Read More
CALGARY, AB & MOUNTAIN VIEW, CA – Willow Biosciences Inc. (“Willow” or the “Company”) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients… Read More
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s Disease Alectos to receive a $15 million upfront payment and is eligible… Read More
VANCOUVER, BC –– InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the closing of its… Read More
The poster at ADA 2022 will highlight the development of Aspect’s bioengineered pancreatic tissue therapeutic VANCOUVER, B.C. – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics… Read More
